SPAG5 Biomarker Expression Analysis for Cancer Prognosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies face challenges in personalization, as 'one size fits all' approaches lead to unnecessary toxicity and ineffective treatments, particularly in identifying aggressive tumors and predicting chemotherapy sensitivity, due to the lack of effective biomarkers for risk assessment and targeted therapy.
Innovation Solution
The method involves determining the expression level of SPAG5 in tumor tissue samples and comparing it to reference values to assess tumor aggressiveness and chemotherapy sensitivity, guiding tailored treatment decisions, including the use of platinum chemotherapy agents, anthracyclines, and HERCEPTIN®, and identifying tumors that may be resistant or sensitive to these treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 'one size fits all' cancer therapy is used, then treatment simplicity is maintained, but treatment effectiveness decreases and unnecessary toxicity increases
Solution Approach 1:
The patent applies local quality by determining SPAG5 expression levels specifically in tumor tissue samples to personalize treatment. Instead of uniform therapy, the treatment approach is tailored based on the local characteristic (SPAG5 expression) of each patient's tumor, enabling effective therapy only for those with high SPAG5 expression and avoiding toxicity in patients with low expression.
Solution Approach 2:
The patent utilizes parameter changes by measuring the expression level of SPAG5 as a biomarker parameter. This parameter serves as the basis for stratifying patients into different treatment groups (high vs. low expression), thereby changing the treatment parameter from uniform to personalized based on the measured biomarker level.
2Reliability
If adjuvant therapy is used for all patients, then potential remaining cancer cells are targeted, but side effects increase and treatment costs increase
Solution Approach 1:
The patent applies local quality by using SPAG5 expression levels to identify which specific patients benefit from adjuvant therapy. Rather than treating all patients uniformly, the therapy is targeted to those with high SPAG5 expression in their tumor tissue, thereby preventing recurrence in high-risk patients while avoiding unnecessary side effects in low-risk patients.
Solution Approach 2:
The patent implements partial action by administering adjuvant therapy only to the subset of patients who have high SPAG5 expression, rather than to all patients. This partial application of therapy optimizes the benefit-risk ratio by providing preventive treatment only where it is most likely to be effective.
3Reliability
If microtubule binding drugs are used, then mitotic spindle function is inhibited, but severe side effects occur due to targeting of non-cancer cells
Solution Approach 1:
The patent applies local quality by using SPAG5 expression as a selective marker to identify cancer cells that are vulnerable to microtubule binding drugs. Patients with high SPAG5 expression are selected for therapy, ensuring that the drugs target cancer cells with the appropriate biomarker while minimizing exposure and potential side effects in patients whose tumors lack this vulnerability marker.
Data Source
AI summary
There has been a recent shift in cancer therapy from one size fits all to a personalized and tailored treatment for individual patients to increase efficiency and avoid unnecessary toxicity. This invention relates to a method of determining the prognosis and suitable treatment of cancer in a subject by measuring the level of expression of SPAG5. In particular, it relates to a method where high expression of SPAG5 in tumour cells correlates with aggressive tumours.